• 1. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Cinnolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Benzodiazines Cinnolines

Introduction to 3,7-Dibromocinnoline (CAS No. 1956370-82-3)

3,7-Dibromocinnoline, identified by the Chemical Abstracts Service Number (CAS No.) 1956370-82-3, is a brominated derivative of cinnoline, a heterocyclic aromatic compound with significant structural and functional versatility. This compound has garnered attention in the field of pharmaceutical chemistry and medicinal research due to its unique molecular framework and potential biological activities. The presence of bromine substituents at the 3 and 7 positions enhances its reactivity and makes it a valuable scaffold for further chemical modifications, enabling the development of novel bioactive molecules.

The molecular structure of 3,7-dibromocinnoline consists of a benzene ring fused with a pyridine ring, with bromine atoms attached at the 3rd and 7th positions relative to the nitrogen atom. This arrangement imparts distinct electronic and steric properties, influencing its interactions with biological targets. The compound’s aromaticity and electron-withdrawing nature make it an attractive candidate for designing inhibitors or modulators of various enzymatic and receptor systems.

In recent years, 3,7-dibromocinnoline has been explored as a key intermediate in the synthesis of pharmacologically active agents. Its brominated structure allows for further functionalization via cross-coupling reactions, such as Suzuki-Miyaura or Buchwald-Hartwig couplings, which are widely employed in drug discovery to introduce diverse substituents. These modifications can tailor the compound’s pharmacokinetic properties, such as solubility, metabolic stability, and target specificity.

One of the most compelling aspects of 3,7-dibromocinnoline is its potential in oncology research. Preliminary studies have suggested that brominated cinnoline derivatives exhibit inhibitory effects on certain kinases and transcription factors involved in cancer cell proliferation. The bromine atoms at positions 3 and 7 play a crucial role in stabilizing reactive intermediates formed during enzyme binding, thereby enhancing binding affinity. Researchers have leveraged this property to design analogs with improved potency against targets such as Janus kinases (JAKs) and cyclin-dependent kinases (CDKs).

Moreover, the structure-activity relationship (SAR) of 3,7-dibromocinnoline has been extensively studied to optimize its therapeutic profile. By systematically varying substituents on the cinnoline core, scientists have identified derivatives that exhibit selective toxicity toward tumor cells while minimizing off-target effects. This approach aligns with the growing demand for precision medicine, where compounds are tailored to interact specifically with disease-causing pathways.

Advances in computational chemistry have further accelerated the development of 3,7-dibromocinnoline-based drugs. Molecular docking simulations and quantum mechanical calculations allow researchers to predict binding affinities and metabolic liabilities before experimental synthesis. These tools have been instrumental in identifying lead compounds that exhibit high efficacy in preclinical models. For instance, virtual screening using 3,7-dibromocinnoline as a template has led to the discovery of novel inhibitors with promising anti-inflammatory and antiviral properties.

The synthetic pathways for 3,7-dibromocinnoline have also seen significant innovation. Traditional methods involving bromination of cinnoline often suffer from poor regioselectivity and yield issues. However, recent developments in catalytic bromination techniques have improved efficiency while maintaining high selectivity for the desired positions. Transition-metal-catalyzed reactions now provide scalable routes to access this compound in multi-kilogram quantities suitable for industrial applications.

In addition to its pharmaceutical applications, 3,7-dibromocinnoline has found utility in materials science. Its ability to form coordination complexes with metal ions makes it a candidate for designing luminescent probes or catalysts. Such applications exploit the compound’s ability to modulate electronic transitions through metal-ligand interactions, opening new avenues in optoelectronic materials.

The future direction of research on 3,7-dibromocinnoline is likely to focus on expanding its therapeutic applications through interdisciplinary collaboration between chemists and biologists. Integration of machine learning algorithms into drug discovery pipelines could further enhance the identification of novel derivatives with enhanced pharmacological profiles. As our understanding of disease mechanisms evolves, compounds like 3,7-dibromocinnoline will continue to serve as critical building blocks for next-generation therapeutics.

• 318276-72-1(6-Bromocinnoline)
• 40598-76-3(3,5-Dibromo-1H-indazole)
• 75608-85-4(Cinnoline, 3,4-dibromo-)
• 78593-33-6(3-Bromocinnoline)
• 40598-94-5(3-Bromo-1H-indazole)
• 24257-88-3(5-Bromocinnoline)
• 3660-91-1(1-bromophthalazine)
• 1375108-47-6(7-Bromocinnoline)
• 885521-84-6(3,6-Dibromo (1h)Indazole)
• 885521-68-6(3,4-Dibromo (1H)indazole)